GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Clinical Oncology (ASCO)  (15)
  • 1
    Online Resource
    Online Resource
    Facilitating patient communication through understanding their social media use: A comparison by age groups.
    American Society of Clinical Oncology (ASCO) ; 2018
    In:  Journal of Clinical Oncology Vol. 36, No. 7_suppl ( 2018-03-01), p. 71-71
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 7_suppl ( 2018-03-01), p. 71-71
    Abstract: 71 Background: Social media and internet is increasingly used by patients for cancer education, which can affect provider-patient communication. Usage habits of the adolescent-young adult (AYA; aged 〈 40 years), adult (age 40- 〈 65 years), and geriatric cancer populations (age 65+ years) are likely different. Methods: Using age-specific sampling, cancer patients across all disease sites cross-sectionally were asked to complete a survey of demographics, health status, and social media/online resource use for cancer education. Clinical information was abstracted. Results: Of 429 approached, 320 participated (126 AYA, 128 adults, 66 elderly). Males comprised 44%; 72% had post-secondary education; 31% had household incomes of 〉 $100,000. Elderly patients were most likely to refuse participation (33% of elderly approached vs 16% AYA; p 〈 0.001), with the most common reason being "I do not use internet resources/don't plan on using them"(96% of all elderly refusals with available data). Among respondents, the proportion who utilized the internet for cancer education was 76%, 76% and 70% in AYA, adults, and elderly, respectively (p 〉 0.5). The use of social media tools in respondents was 49%, 40%, and 36%, respectively (p = 0.16 across age groups). While 75% of patients felt they could judge the quality of cancer-related information on the internet (no differences by age group, p 〉 0.5), a significantly lower 43% (p 〈 0.001) felt similarly confident to judge the quality of social media; AYA patients (49%) were numerically more likely to feel confident than seniors (36%; p = 0.16). Elderly were less likely to want online health record access (p = 0.015), treatment option (p = 0.042) and side effect education (p 〈 0.001), future care plan (p 〈 0.001) and wellness programs compared to others (p 〈 0.001). Conclusions: Although cancer patients used social media frequently, confidence is lacking on the quality of cancer information obtained (across all age groups), while elderly perceive fewer benefits of using online/social media related to their cancer. Guidelines for patients on how to assess quality and appropriately use social media could help facilitate patient-provider communication.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2018.36.7_suppl.71
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 15_suppl ( 2020-05-20), p. 3581-3581
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. 3581-3581
    Abstract: 3581 Background: LY2880070 (LY) is an oral, selective competitive inhibitor of checkpoint kinase 1 (Chk1). Chk1 inhibitors are known to increase the anti-tumor efficacy of agents such as gemcitabine (GEM), which induce replication stress. Synergy between these two agents has been applied to the clinical setting. Methods: This two-part, open-label multi-center study explores the safety, pharmacokinetics (PK), and anti-tumor activity of LY in patients with advanced or metastatic cancers. The primary objective of this study was to determine the maximum tolerated dose (MTD) for multiple escalating oral doses of LY in combination with GEM. Secondary objectives were to: 1) Characterize the dose-limiting toxicities (DLTs) and overall safety profile for LY; 2) Evaluate the PK of LY; and 3) Evaluate the anti-tumor activity of LY. Patients received LY in a variety of different dose regimens, in combination with GEM (50 to 800 mg/m 2 ) on days 1, 8, and 15 (optional) of a 21-day cycle. Results: The combination of LY with GEM required lower doses of both LY (vs 200 mg BID monotherapy RP2D dose) and GEM (vs approved doses). The dose levels explored ranged from LY:GEM of 10 mg QD:800 mg/m 2 to 50 mg BID:100 mg/m 2 . BID dosing of LY was implemented in order to maximize the total daily dose and avoid the adverse events that appeared to correlate with C max . Treatment-emergent adverse events in 〉 40% of patients included vomiting, nausea, and fatigue. DLTs included reduced platelet count (Gr2), fatigue (Gr3), diarrhea (Gr3), and thrombocytopenia (x2, Gr2). The t 1/2 of LY was ~ 5 h, and was not significantly affected by combination with GEM. Two patients had a best overall response of SD for a duration of ≥ 6 cycles, and a confirmed PR was observed in an ovarian cancer patient who had failed multiple regimens. Conclusions: LY was tolerated in combination with lower dose GEM. The toxicity profile can be modulated by changing the dosing frequency from QD to BID while administering the same daily dose. LY may be good candidate for combination therapy with DNA damaging agents. Clinical trial information: NCT02632448 .
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2020.38.15_suppl.3581
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Assessment of language needs and resource use among Canadian immigrant patients with cancer.
    American Society of Clinical Oncology (ASCO) ; 2018
    In:  Journal of Clinical Oncology Vol. 36, No. 30_suppl ( 2018-10-20), p. 77-77
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 30_suppl ( 2018-10-20), p. 77-77
    Abstract: 77 Background: Canada's foreign-born population is estimated to reach up to 30% by 2036. Immigrants diagnosed with cancer can face poorer cancer outcomes compared to non-immigrants due to language barriers affecting physician-patient communication and non-equivalent interpretation by untrained translators. Reducing this disparity is a growing challenge due to continued high immigration rates. As Canadian data is lacking, we explored the language needs and resource utilization of Canadian cancer patients. Methods: Adult cancer survivors from Princess Margaret Cancer Centre were surveyed in English on their socio-demographics, perceived communication difficulties, and interpreter use. Results: Of 470 patients, 45% were foreign-born; 37% self-identified as immigrants; 78% spoke mostly English at home. Among self-identified immigrants, median age at diagnosis was 60 years, 46% were female, and 59% completed post-secondary education. Top three countries of origin were China (23%), India (10%), and Italy (9%). Although 73% of immigrants reported English as their most comfortable language in which to receive healthcare information, 18% reported difficulties communicating with the doctor in English at a few visits or more, 14% indicated some discomfort communicating with their oncologist in English, and 4% of immigrants felt their cancer care was affected by a language barrier. Twenty-six percent of immigrants required interpretation, with 91% employing family, 7% utilizing professional interpreters, and only 19% have ever used the institutional language services. Conclusions: Although most immigrants identify English as their most comfortable language for healthcare delivery, some still experience communication difficulties with their oncologist during at least a few visits. However, most patients felt comfortable communicating with their oncologists and do not feel their cancer care is affected. Most relied on family members to interpret, while local hospital language resources were largely underutilized. Strategies for promoting professional translation service use may help improve immigrants’ experience, caregivers’ burden, and enhance physicians’ ability to counsel patients directly.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2018.36.30_suppl.77
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Phase I study of NEROFE and doxorubicin in KRAS -mutated ST2-positive solid tumors.
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. TPS2667-TPS2667
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. TPS2667-TPS2667
    Abstract: TPS2667 Background: KRAS-mutated tumors are notoriously difficult to treat clinically with targeted therapies. Recent advances targeting KRAS G12C with sotorasib and adagrasib are encouraging but limited to a small subset of patients. NEROFE is a 14 amino acid peptide which inhibits suppression of tumorigenicity 2 (ST2; member of the interleukin 1 [IL-1] receptor family and IL-33 receptor), a novel immune checkpoint present on tumor cells and tumor-associated macrophages. ST2 blockade with NEROFE has been shown to transform an immunosuppressive tumor microenvironment into an immune-stimulatory microenvironment. NEROFE also has been shown to induce microRNA miR-217 which downregulates KRAS and MAPK1/2 gene expression in preclinical models. When combined with low-dose doxorubicin, NEROFE has a synergistic effect on inducing apoptosis in KRAS-mutated, ST2-positive cell lines and xenograft models. Methods: This is a phase I trial of NEROFE given at 48 mg/m 2 (dose level [DL] -1), 96 mg/m 2 (DL1), 192 mg/m 2 (DL2), or 288 mg/m 2 (DL3) IV weekly with doxorubicin 8 mg/m 2 IV weekly. A standard 3+3 dose escalation/de-escalation is used. The primary objective is to determine the recommended phase II dose. Patients are eligible if they have an advanced solid tumor with a KRAS mutation and ST2-positivity (via immunohistochemistry [IHC], centrally confirmed with pre-screening allowed). Patients must have measurable disease amenable to serial biopsy. Patients must have had progression or intolerance to all standard therapies or must decline available standard therapy. Pharmacokinetic profiles will be analyzed from serial blood draws pre- and 1, 2, 4, 6, and 24 hours post-infusion on cycle 1 day and cycle 2 day 1. Pre- and on-treatment tumor biopsies are mandatory. Correlative studies include IHC for ST2 expression, immune cell infiltration and blood-based analyses of KRAS mRNA, miR-217, and cytokines. Enrollment to DL1 began in Q1 2023 (NCT05661201). Clinical trial information: NCT05661201 .
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2023.41.16_suppl.TPS2667
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Clinical Oncology Vol. 37, No. 15_suppl ( 2019-05-20), p. e20667-e20667
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. e20667-e20667
    Abstract: e20667 Background: The tissue microenvironment associated with specific organ metastases potentially influences the efficacy of checkpoint inhibitors. The presence of liver metastases is a predictor of poor response and survival in melanoma and is correlated with reduced CD8+ T cell infiltration. Our study examined clinicopathologic characteristics, focusing on sites of metastatic disease, that are associated with poor outcomes. Methods: Advanced NSCLC patients treated with ≥1 cycle of ICI were reviewed. Baseline age, sex, histology, stage, smoking status, ethnicity, PD-L1 expression and sites of metastases were recorded. Best overall response (BOR) was determined by clinical imaging response and categorized ordinally as shrinkage, stable, or progression, adapted from RECIST for CR/PR, SD, PD. A rapidly progressive phenotype (RPP) was defined as BOR of progression and ICI use of ≤2 months. The association between sites of metastases and clinical outcomes were investigated using logistic and cox regression models. Results: Among 219 eligible patients, bone was the most common metastatic site (34.7%), followed by brain (21.5%), adrenals (14.2%), and liver (13.7%). Bone metastases (OR 0.45, p = 0.004) were associated with a worse BOR, while only a trend was observed for liver metastases (OR 0.47, p = 0.06). Adrenal metastases were associated with a better BOR (OR 2.08, p = 0.04). But thorax limited disease did not associate with BOR (OR 1.08, p = 0.76). In a multivariate model, bone was the only metastatic site associated with a worse BOR (OR 0.50, p = 0.01). Further, bone metastases were associated with RPP (adjusted OR 1.91, p = 0.04). Both bone (adjusted hazard ratio/aHR 1.61, p = 0.01) and liver metastases (aHR 1.80, p = 0.02) were associated with a shorter time-to-treatment-failure. The presence of liver (aHR 2.63, p 〈 0.001) but not bone (aHR 1.04, p = 0.86) metastases was a significant predictor of poor OS. Conclusions: We report a novel finding that the presence of bone metastases was associated with a worse clinical overall response on ICI and a rapidly progressive phenotype. Further investigations into the mechanisms of RPP in the presence of bone metastases are needed.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2019.37.15_suppl.e20667
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Comparison of health care-related social media and Internet usage between patients treated with curative and palliative intent.
    American Society of Clinical Oncology (ASCO) ; 2018
    In:  Journal of Clinical Oncology Vol. 36, No. 34_suppl ( 2018-12-01), p. 173-173
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 34_suppl ( 2018-12-01), p. 173-173
    Abstract: 173 Background: Cancer patients (pts) are increasingly searching online for information and support. Online resource usage and preferences may differ between patients treated with curative versus palliative intent. Methods: Cancer pts completed a cross-sectional survey at Princess Margaret Cancer Centre, assessing their usage and perceptions of social media and the internet with regards to their cancer. Associations between patients’ responses and treatment intent were evaluated univariably (t-tests, chi-squared tests) and multivariably (linear/logistic regression). Results: In a univariable analysis comparing 65 palliative pts (PALL) and 222 curative pts, PALL were more likely to be older (p 〈 0.001) and less likely to be currently employed or a student (p 〈 0.001); they were less likely to use the internet (91% vs. 97%, p = 0.03), social media (68% vs. 87%, p 〈 0.001), and used social media less frequently than curative patients (66% vs. 83%, p = 0.01). PALL were less likely to be interested in an online personal health record (62% vs 76%, p = 0.04) and more likely to indicate that they would not use online information (17% vs. 7%, p = 0.02), compared to curative pts. PALL were more likely to be unfamiliar with social media (20% vs. 7%, p = 0.01), to not know how to use social media (21% vs. 7%, p 〈 0.001), and to have difficulty finding information (14% vs. 5%, p = 0.03). However, no significant differences by intent were identified after adjustment in a multivariable analysis controlling for age. Conclusions: After the age differences between both groups were adjusted for, there were no significant differences in patients’ online activity nor their perceptions of the trustworthiness, utility, and role of social media, and the Internet. These similarities suggest that online resources for PALL can be developed simultaneously with curative pts.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2018.36.34_suppl.173
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
    American Society of Clinical Oncology (ASCO) ; 2021
    In:  Journal of Clinical Oncology Vol. 39, No. 7 ( 2021-03-01), p. 807-821
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 7 ( 2021-03-01), p. 807-821
    Abstract: We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular features between patient-matched diagnostic and relapsed tumors. METHODS Children and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and temporal patterns of relapse and postrelapse survival. A largely independent, paired molecular cohort was analyzed by DNA methylation array and next-generation sequencing. RESULTS A total of 72 of 329 (22%) SJMB03 and 52 of 79 (66%) SJYC07 patients experienced relapse with significant representation of Group 3 and wingless tumors. Although most patients exhibited some distal disease (79%), 38% of patients with sonic hedgehog tumors experienced isolated local relapse. Time to relapse and postrelapse survival varied by molecular subgroup with longer latencies for patients with Group 4 tumors. Postrelapse radiation therapy among previously nonirradiated SJYC07 patients was associated with long-term survival. Reirradiation was only temporizing for SJMB03 patients. Among 127 patients with patient-matched tumor pairs, 9 (7%) experienced subsequent nonmedulloblastoma CNS malignancies. Subgroup (96%) and subtype (80%) stabilities were largely maintained among the remainder. Rare subgroup divergence was observed from Group 4 to Group 3 tumors, which is coincident with genetic alterations involving MYC, MYCN, and FBXW7. Subgroup-specific patterns of alteration were identified for driver genes and chromosome arms. CONCLUSION Clinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radiation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular conservation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification of occult secondary malignancies.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.20.01359
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors.
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Clinical Oncology Vol. 37, No. 31_suppl ( 2019-11-01), p. 141-141
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 31_suppl ( 2019-11-01), p. 141-141
    Abstract: 141 Background: Health behaviors including tobacco use, alcohol consumption, and physical activity (PA) can impact outcomes in cancer survivors. While the peri-diagnostic period can be a "teachable moment" for behavior change, patients may face barriers including mental health comorbidities. We have previously identified that patient perceptions of behaviors can influence behavior change. Here, we evaluated the impact of anxiety and depression on patient perceptions of these behaviors. Methods: Cancer patients from all disease sites were surveyed (2016-17) on their smoking, alcohol habits, and PA, and perceptions of the impact of these behaviors on fatigue, survival, and quality of life (QofL). Survey data were linked with same day Edmonton Symptom Assessment Symptom (ESAS) anxiety and depression scores. Logistic regression models evaluated the impact of anxiety and depression on patient perceptions. Results: Of 496, 53% were male; median age, 60 years. At diagnosis, 20% were current smokers, 47% were current drinkers, and 67% were not meeting PA guidelines. 30% screened positive for anxiety (ESAS anxiety 〉 3) and 34% screened positive for depression (ESAS depression 〉 2); mean [standard deviation] scores were 1.9 [2.3] for anxiety and 1.5 [2.2] for depression. Most current smokers ( 〉 80%) perceived smoking to negatively impact fatigue, survival and QofL. Smokers screening positive for anxiety were more likely to perceive smoking as harmful on survival (OR=9.09, 95% CI (1.15-100), P=0.04); greater ESAS anxiety scores were associated with perceiving smoking to worsen survival (OR=1.51 per point, 95% CI (1.04-2.17), P=0.03). While those less physically active at diagnosis ( 〉 65%) felt that PA improves fatigue, survival and QofL and half of current drinkers (45%-50%) felt that alcohol worsens outcomes, anxiety and depression were not found associated with perceptions (P 〉 0.10). Conclusions: Among current smokers, greater anxiety scores and those screening positive for anxiety were more likely to perceive continued smoking as harmful to survival. Mental health comorbidities were not found to have an impact on patient perceptions of the effect of alcohol consumption and PA on fatigue, survival, and QofL.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2019.37.31_suppl.141
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.
    American Society of Clinical Oncology (ASCO) ; 2018
    In:  Journal of Clinical Oncology Vol. 36, No. 15_suppl ( 2018-05-20), p. 9048-9048
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 15_suppl ( 2018-05-20), p. 9048-9048
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2018.36.15_suppl.9048
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Clinical Oncology Vol. 37, No. 8_suppl ( 2019-03-10), p. 82-82
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 8_suppl ( 2019-03-10), p. 82-82
    Abstract: 82 Background: Immune checkpoint inhibitors (ICI) are improving the care of cancer patients. Despite being better tolerated than chemotherapy, there is a risk of developing irAEs which may require hospitalization. Although ICI and irAEs are well studied in clinical trials, there is a paucity of studies characterizing the care patterns for real-world irAEs hospitalizations. Methods: A single centre retrospective chart review (Princess Margaret Cancer Centre, Toronto, ON) identified patients receiving standard of care ICI (2012-2017) hospitalized for irAEs. For hospitalizations, clinico-pathological, investigation and treatment details were collected. Descriptive statistics helped to characterize hospitalizations. Results: Among 697 patients (266 lung, 381 melanoma and 50 genitourinary (GU)) on ICI, 8% (14 lung, 41 melanoma and 2 GU) had at least 1 irAE (range 1-4) hospitalization for a total of 69 hospitalizations. Average length of stay was 12 days (range 1-105). Among hospitalized patients, median age was 60; 63% were male; 29% received ipilimumab monotherapy, 28% pembrolizumab, 22% nivolumab and 22% received combination ICI. The most common irAEs were colitis (52%), pneumonitis (20%), hepatitis (10%) and CNS disease (demyelination, hypophysis) (9%). Cases were admitted directly from clinic (39%), emergency rooms (29%), urgent care clinic (18%) or transferred from another hospital (13%). Most patients (72%) were admitted to oncology; 28% to general medicine. Endoscopy was performed in 21% of admissions with 60% showing evidence of irAE; biopsies were obtained in 16% of admissions and 73% had evidence of irAE. Subspecialty services were involved in 60% of admissions. Most patients received steroids (94%); 17% received Infliximab. While age did not impact length of stay (p = 0.63), patients admitted to oncology had longer admissions compared to general medicine (14 vs 6 days, p = 0.009). Conclusions: irAEs occur at similar rates in the real-world compared to clinical trials. There is significant heterogeneity in the care patterns for irAEs. Patients admitted to oncology had longer average lengths of stay. Further characterizing irAE can help to develop quality indicators that may improve irAE outcomes.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2019.37.8_suppl.82
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...